Targeted Oncology To Launch Virtual Tumor Board
<em>Targeted Oncology</em>™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 30. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field.
Targeted Oncology™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 30. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This first one will focus on chronic lymphocytic leukemia (CLL).
“We are thrilled to introduce this educational platform for community-based oncologists,” said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of Targeted Oncology™. “Through this initiative, we look forward to empowering oncologists by providing them with the latest updates from their specific field of practice.”
The Virtual Tumor Board will feature multiple experts that will provide an in-depth analysis on CLL diagnosis, biomarker testing and therapeutic approaches from a collaborative medical setting. Together, these experts will provide a focused look at multiple case sets from a treatment team perspective to further educate community-based oncologists in this comprehensive series of practice-changing insights.
Key opinion leaders for this virtual tumor board are:
- Matthew Davids, M.D., MMSc., associate director, Center for Chronic Lymphocytic Leukemia, physician, Dara-Farber Cancer Center, assistant professor of medicine, Harvard Medical School
- William Wierda, M.D., Ph.D., D.B.Lane Cancer Research Distinguished professor, department of leukemia, division of cancer medicine, executive medical director, professor, department of leukemia, division of cancer medicine, section chief chronic lymphocytic leukemia, department of leukemia, division of cancer medicine, center medical director, department of leukemia, division of cancer medicine, The University of Texas MD, Anderson Cancer Center
- Nitin Jain, M.D., assistant professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center
- Adam Bagg, M.D., professor, department of pathology and laboratory medicine, Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine
About Targeted Oncology
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More
